MD4341C1 - Syrup for the treatment of gastric precancerous conditions - Google Patents
Syrup for the treatment of gastric precancerous conditions Download PDFInfo
- Publication number
- MD4341C1 MD4341C1 MDA20130088A MD20130088A MD4341C1 MD 4341 C1 MD4341 C1 MD 4341C1 MD A20130088 A MDA20130088 A MD A20130088A MD 20130088 A MD20130088 A MD 20130088A MD 4341 C1 MD4341 C1 MD 4341C1
- Authority
- MD
- Moldova
- Prior art keywords
- vitamin
- syrup
- treatment
- nanoparticles
- precancerous conditions
- Prior art date
Links
- 235000020357 syrup Nutrition 0.000 title claims abstract description 16
- 239000006188 syrup Substances 0.000 title claims abstract description 16
- 238000011282 treatment Methods 0.000 title claims abstract description 16
- 208000006994 Precancerous Conditions Diseases 0.000 title claims abstract description 11
- 230000002496 gastric effect Effects 0.000 title claims abstract description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 14
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 14
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 12
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002105 nanoparticle Substances 0.000 claims abstract description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 7
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 7
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960002061 ergocalciferol Drugs 0.000 claims abstract description 7
- 229960002477 riboflavin Drugs 0.000 claims abstract description 7
- 229960003495 thiamine Drugs 0.000 claims abstract description 7
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims abstract description 7
- 235000001892 vitamin D2 Nutrition 0.000 claims abstract description 7
- 239000011653 vitamin D2 Substances 0.000 claims abstract description 7
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 6
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 6
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 6
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 6
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 6
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910052709 silver Inorganic materials 0.000 claims abstract description 6
- 239000004332 silver Substances 0.000 claims abstract description 6
- 235000020374 simple syrup Nutrition 0.000 claims abstract description 6
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 6
- 239000011719 vitamin A Substances 0.000 claims abstract description 6
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 6
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 6
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 6
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 6
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 6
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 6
- 239000011718 vitamin C Substances 0.000 claims abstract description 6
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 6
- 239000011709 vitamin E Substances 0.000 claims abstract description 6
- 229940046009 vitamin E Drugs 0.000 claims abstract description 6
- 229940045997 vitamin a Drugs 0.000 claims abstract description 6
- 239000011787 zinc oxide Substances 0.000 claims abstract description 6
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000005751 Copper oxide Substances 0.000 claims abstract description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 5
- 229960002685 biotin Drugs 0.000 claims abstract description 5
- 235000020958 biotin Nutrition 0.000 claims abstract description 5
- 239000011616 biotin Substances 0.000 claims abstract description 5
- 229910000431 copper oxide Inorganic materials 0.000 claims abstract description 5
- 229960000304 folic acid Drugs 0.000 claims abstract description 5
- 235000019152 folic acid Nutrition 0.000 claims abstract description 5
- 239000011724 folic acid Substances 0.000 claims abstract description 5
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 5
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 5
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 5
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 5
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 5
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 5
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 5
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000011655 sodium selenate Substances 0.000 claims abstract description 4
- 229960001881 sodium selenate Drugs 0.000 claims abstract description 4
- 235000018716 sodium selenate Nutrition 0.000 claims abstract description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract 3
- 239000004615 ingredient Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 4
- 239000013543 active substance Substances 0.000 abstract description 3
- 235000012245 magnesium oxide Nutrition 0.000 abstract description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 abstract 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 abstract 1
- 229960004643 cupric oxide Drugs 0.000 abstract 1
- 229960000869 magnesium oxide Drugs 0.000 abstract 1
- 229940055726 pantothenic acid Drugs 0.000 abstract 1
- 235000019161 pantothenic acid Nutrition 0.000 abstract 1
- 239000011713 pantothenic acid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 5
- 230000002411 adverse Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 235000014066 European mistletoe Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 2
- 240000007313 Tilia cordata Species 0.000 description 2
- 241000221012 Viscum Species 0.000 description 2
- 239000011852 carbon nanoparticle Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- -1 polyethylene terephthalate Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XWKBMOUUGHARTI-UHFFFAOYSA-N tricalcium;diphosphite Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])[O-].[O-]P([O-])[O-] XWKBMOUUGHARTI-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004231 Riboflavin-5-Sodium Phosphate Substances 0.000 description 1
- 241000983746 Saccharina latissima Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- TVZISJTYELEYPI-UHFFFAOYSA-N hypodiphosphoric acid Chemical compound OP(O)(=O)P(O)(O)=O TVZISJTYELEYPI-UHFFFAOYSA-N 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000011683 manganese gluconate Substances 0.000 description 1
- 235000014012 manganese gluconate Nutrition 0.000 description 1
- 229940072543 manganese gluconate Drugs 0.000 description 1
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019234 riboflavin-5-sodium phosphate Nutrition 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Invenţia se referă la gastroenterologie, în special la substanţe biologic active în formă de siropuri care pot fi utilizate pentru tratamentul stărilor precanceroase gastrice. The invention relates to gastroenterology, in particular to biologically active substances in the form of syrups that can be used for the treatment of gastric precancerous conditions.
Se cunoaşte că depistarea şi tratamentul stărilor precanceroase ale stomacului reprezintă profilaxia secundară a cancerului gastric (Беспалов В. Г. Индивидуальная профилактика рака. Питер, 2001, с. 123-126). It is known that the detection and treatment of pre-cancerous conditions of the stomach represent the secondary prophylaxis of gastric cancer (Беспалов В. Г. Индивидеольная профилактия рака. Питер, 2001, с. 123-126).
În prezent la principalele stări precanceroase ale stomacului se referă gastrita cronică atrofică şi infectarea cu Helicobacter pylori, iar la schimbările precanceroase principale se referă metaplazia intestinală şi displazia intestinală a epiteliului gastric (Аруин Л. И., Капуллер Л. Л., Исаков В. А. Морфологическая диагностика желудка и кишечника. Москва, Триада-Х, 1998, с. 269-300). Currently, chronic atrophic gastritis and Helicobacter pylori infection are the main precancerous conditions of the stomach, and intestinal metaplasia and intestinal dysplasia of the gastric epithelium are the main precancerous changes (Аруин Л. И., Капуллер Л. Л., Исаков В. A. Morphological diagnosis of the stomach and intestines. Moscow, Triada-X, 1998, pp. 269-300).
Este cunoscută metoda de tratament al stărilor precanceroase gastrice, care constă în aceea că se administrează un remediu medicamentos care conţine decoct din flori de tei şi din partea aeriană de vâsc alb, amestec din mediul de cultură RPMI 1640 şi celule stem, extract proteic din ţesut tumoral, în următorul raport al componentelor, în % mas.: decoct din flori de tei 10, decoct din partea aeriană de vâsc alb 20, amestec din mediul de cultură RPMI 1640 şi celule stem 35, extract proteic din ţesut tumoral 35, administrarea se efectuează per os, de 4…5 ori pe zi, cu 30 min înainte de masă, cate 20 ml, timp de 60…120 zile [1]. There is a known method of treating gastric precancerous conditions, which consists in the administration of a medicinal remedy containing a decoction of linden flowers and the aerial part of white mistletoe, a mixture of RPMI 1640 culture medium and stem cells, protein extract from tissue tumor, in the following ratio of the components, in mass %: decoction of linden flowers 10, decoction of the aerial part of white mistletoe 20, mixture of culture medium RPMI 1640 and stem cells 35, protein extract from tumor tissue 35, the administration is perform orally, 4...5 times a day, 30 min before meals, 20 ml each, for 60...120 days [1].
Dezavantajul acestei metode constă în aceea că este complicată în vederea obţinerii remediului medicamentos şi poate provoca reacţii alergice la pacienţii cu astm bronşic. The disadvantage of this method is that it is complicated in order to obtain the medicinal remedy and can cause allergic reactions in patients with bronchial asthma.
Mai este cunoscută metoda de tratament al stărilor precanceroase gastrice, care constă în aceea că se administrează remediul KLAMIN (concentrat din Laminaria saccharina L. Lamour), obţinut din fracţia lipidică a algelor brune de mare, câte 2 pastile de trei ori pe zi, cu 15…30 min înainte de masă, timp de 6 luni, cu repetarea curei de tratament peste 1…3 luni [2]. There is also a known method of treating gastric precancerous conditions, which consists in administering the remedy KLAMIN (concentrate from Laminaria saccharina L. Lamour), obtained from the lipid fraction of brown seaweed, 2 pills three times a day, with 15...30 min before meals, for 6 months, with the repetition of the treatment course after 1...3 months [2].
Dezavantajul acestei metode constă în aceea că remediul KLAMIN conţine iod, din care cauză este contraindicat persoanelor care suferă de tireotoxicoză, insuficienţă renală şi hepatică cronică. The disadvantage of this method is that the KLAMIN remedy contains iodine, which is why it is contraindicated for people suffering from thyrotoxicosis, chronic kidney and liver failure.
Se cunoaşte de asemenea o metodă de tratament al stărilor precanceroase gastrice, care constă în aceea că se administrează per os o compoziţie care conţine vitamina E şi β-caroten [3]. A method is also known for the treatment of gastric precancerous conditions, which consists in the fact that a composition containing vitamin E and β-carotene is administered orally [3].
Dezavantajul acestei metode constă în aceea că compoziţia se administrează timp îndelungat, devenind posibilă cumularea vitaminei liposolubile în organism, ceea ce poate duce la manifestarea unui şir de efecte adverse. The disadvantage of this method is that the composition is administered for a long time, making it possible to accumulate the fat-soluble vitamin in the body, which can lead to the manifestation of a series of adverse effects.
Este cunoscut un supliment alimentar, denumit şi „Vidaylin-m - sirop”, administrat în patologiile gastro-intestinale pentru tratamentul gastritei cronice atrofice ce conţine: retinol (vitamina A - sub formă de palmitat) 0,9 mg (3000 UI, ergocalciferol (vitamina D2) 10 mg (400 UI), tiamină (vitamina B1 - sub formă de clorhidrat) 1,5 mg, riboflavină (vitamina B2 - sub formă de riboflavina-5-sodiu fosfat) 1,2 mg, piridoxină (vitamina B6 - sub formă de clorhidrat) 1 mg, ciancobalamină (vitamina B12) 3 mg, acid ascorbic (vitamina C) 50 mg, nicotinamidă 10 mg, pantenol 5 mg, fosfor (sub formă hipofosfat de calciu şi acid hipofosforic) 43 mg, calciu (sub formă de lactat de calciu şi hipofosfat de calciu) 40 mg, magneziu (sub formă de gluconat de magneziu) 3 mg, zinc (sub formă de glucoheptonat de zinc) 0,5 mg, iod (sub formă de iodură de potasiu) 75 mg, mangan (sub formă de gluconat de mangan) 0,5 mg, fier (sub formă de Fe II-gluconat) 3 mg, colină (sub formă de bitartrat de colină) 5 mg, ionozitol 5 mg [4]. A food supplement is known, also called "Vidaylin-m - syrup", administered in gastrointestinal pathologies for the treatment of chronic atrophic gastritis, which contains: retinol (vitamin A - in the form of palmitate) 0.9 mg (3000 IU, ergocalciferol ( vitamin D2) 10 mg (400 IU), thiamine (vitamin B1 - in the form of hydrochloride) 1.5 mg, riboflavin (vitamin B2 - in the form of riboflavin-5-sodium phosphate) 1.2 mg, pyridoxine (vitamin B6 - as hydrochloride) 1 mg, cyanocobalamin (vitamin B12) 3 mg, ascorbic acid (vitamin C) 50 mg, nicotinamide 10 mg, panthenol 5 mg, phosphorus (as calcium hypophosphate and hypophosphoric acid) 43 mg, calcium (as form of calcium lactate and calcium hypophosphate) 40 mg, magnesium (as magnesium gluconate) 3 mg, zinc (as zinc glucoheptonate) 0.5 mg, iodine (as potassium iodide) 75 mg , manganese (in the form of manganese gluconate) 0.5 mg, iron (in the form of Fe II-gluconate) 3 mg, choline (in the form of choline bitartrate) 5 mg, ionositol 5 mg [4].
Dezavantajul acestui supliment constă în aceea că are o acţiune insuficientă asupra evoluţiei gastritei cronice atrofice şi chiar la administrări îndelungate (timp de 8 luni) nu produce efecte semnificative de tratament, adică la fibrogastroscopie se atestă atrofia mucoasei gastrice, dar pe suprafaţe mai mici faţă de cele determinate înainte de tratament, totodată contribuie la cumularea vitaminelor liposolubile în organism, ceea ce duce la manifestarea unui şir de efecte adverse. The disadvantage of this supplement is that it has insufficient action on the evolution of chronic atrophic gastritis and even with prolonged administration (for 8 months) it does not produce significant treatment effects, i.e. at fibrogastroscopy atrophy of the gastric mucosa is attested, but on smaller surfaces compared to those determined before the treatment, also contribute to the accumulation of fat-soluble vitamins in the body, which leads to the manifestation of a series of adverse effects.
În ultimul deceniu au fost efectuate mai multe cercetări în domeniul structurilor de carbon, îndeosebi a nanoparticulelor de carbon şi microcorpusculilor de 1…10 nm. Pentru prima dată nanoparticulele de carbon au fost sintetizate în 1963 şi au fost aplicate în diverse tehnologii industriale. Semnificativ este faptul că în procesul activităţii acestor nanoparticule are loc degajarea de căldură. In the last decade, several researches were carried out in the field of carbon structures, especially carbon nanoparticles and microcorpuscles of 1...10 nm. For the first time carbon nanoparticles were synthesized in 1963 and were applied in various industrial technologies. It is significant that in the process of the activity of these nanoparticles heat is released.
O particularitate semnificativă a nanoparticulelor este că ele pătrund în membrana celulară şi pot precipita la suprafaţa sferică a mai multor celule substanţe biologic active, medicamente, polimeri etc. Aceste caracteristici au stat la baza aplicării nanoparticulelor cu scop de dezintoxicare şi în calitate de conductor. În aşa fel, în anul 2000 nanoparticulele au fost folosite la pacienţii oncologici care au fost supuşi radio- şi chimioterapiei, cu scop de dezintoxicare. A significant feature of nanoparticles is that they penetrate the cell membrane and can precipitate biologically active substances, drugs, polymers, etc. on the spherical surface of several cells. These characteristics were the basis for the application of nanoparticles for the purpose of detoxification and as a conductor. In this way, in the year 2000, nanoparticles were used in oncological patients who were subjected to radio- and chemotherapy, with the aim of detoxification.
Problema pe care o soluţionează invenţia propusă constă în crearea unui supliment alimentar în formă de sirop, care ar avea efecte vizibile în tratamentul stărilor precanceroase gastrice, ar reduce durata de tratament fără manifestarea unui şir de efecte adverse. The problem that the proposed invention solves consists in the creation of a food supplement in the form of syrup, which would have visible effects in the treatment of gastric precancerous conditions, would reduce the duration of treatment without the manifestation of a series of adverse effects.
Conform invenţiei, siropul revendicat conţine: vitamina A, vitamina D2, vitamina E, vitamina C, vitamina B1, vitamina B2, niacină, vitamina B6, vitamina B12, biotină, acid folic, acid pantoteic, oxid de magneziu, oxid de cupru, selenat de sodiu, nanoparticule de oxid de zinc şi argint, luate în raport de 9:1, şi sirop de zahăr, ingredientele fiind luate în următorul raport cantitativ pentru 100 ml: According to the invention, the claimed syrup contains: vitamin A, vitamin D2, vitamin E, vitamin C, vitamin B1, vitamin B2, niacin, vitamin B6, vitamin B12, biotin, folic acid, pantotheic acid, magnesium oxide, copper oxide, selenate of sodium, nanoparticles of zinc oxide and silver, taken in a ratio of 9:1, and sugar syrup, the ingredients being taken in the following quantitative ratio for 100 ml:
vitamina A, mg 0,8 vitamina D2, mg 0,005 vitamina E, mg 10 vitamina C, mg 100 vitamina B1, mg 3 vitamina B2, mg 3,6 niacină, mg 40 vitamina B6, mg 2 vitamina B12, mg 0,003 biotină, mg 0,06 acid folic, mg 0,2 acid pantoteic, mg 15 oxid de magneziu, mg 375 oxid de cupru, mg 1 selenat de sodiu, mg 0,055 nanoparticule de oxid de zinc şi argint, mg 6 sirop de zahăr, ml restul. vitamin A, mg 0.8 vitamin D2, mg 0.005 vitamin E, mg 10 vitamin C, mg 100 vitamin B1, mg 3 vitamin B2, mg 3.6 niacin, mg 40 vitamin B6, mg 2 vitamin B12, mg 0.003 biotin, mg 0.06 folic acid, mg 0.2 pantotheic acid, mg 15 magnesium oxide, mg 375 copper oxide, mg 1 sodium selenate, mg 0.055 nanoparticles of zinc oxide and silver, mg 6 sugar syrup, ml the rest .
Rezultatul invenţiei constă în obţinerea unui supliment alimentar în formă de sirop, care are efecte vizibile în tratamentul complet al stărilor precanceroase gastrice, timp de 3 luni, datorită selectării reuşite a vitaminelor şi a raportului lor în combinaţie cu microelementele şi nanoparticulele de oxid de argint şi de zinc luate în raport de 9:1, care pătrund mult mai uşor în celulele mucoasei. The result of the invention consists in obtaining a food supplement in the form of syrup, which has visible effects in the complete treatment of gastric precancerous conditions, for 3 months, due to the successful selection of vitamins and their ratio in combination with microelements and nanoparticles of silver oxide and of zinc taken in a ratio of 9:1, which penetrate much more easily into the cells of the mucosa.
Siropul nutriţional se prepară în felul următor. The nutritional syrup is prepared in the following way.
Ingredientele se selectează conform invenţiei, se cântăresc conform cantităţilor revendicate. Ingredientele se folosesc sub formă de pulbere. Apoi se prepară 100 ml de sirop din zahăr în felul următor: 64 g de zahăr se dizolvă în apă caldă de 70°C timp de 1…2 min, agitându-se permanent. Siropul se trece prin aparatul cu vapori-vid şi se pasteurizează în aparatul cu vapori-vid, timp de cel puţin 20 min, la temperatura de 98…100ºC. Apoi la ingredientele pregătite, care în total constituie 556,723 mg, se adaugă siropul pregătit şi răcit până la 20°C şi se malaxează timp de 10 min. Indicele de refracţie al siropului nutriţional trebuie să fie de 1,4486…1,4532. Caracteristicile organoleptice ale siropului sunt: netransparent, de culoare uşor gălbuie, cu miros specific şi gust dulce amărui. The ingredients are selected according to the invention, weighed according to the claimed quantities. The ingredients are used in powder form. Then prepare 100 ml of sugar syrup in the following way: dissolve 64 g of sugar in warm water at 70°C for 1...2 min, stirring constantly. The syrup is passed through the steam-vacuum machine and pasteurized in the steam-vacuum machine for at least 20 min, at a temperature of 98...100ºC. Then to the prepared ingredients, which in total constitute 556.723 mg, add the prepared syrup cooled to 20°C and mix for 10 min. The refractive index of the nutritional syrup must be 1.4486...1.4532. The organoleptic characteristics of the syrup are: non-transparent, slightly yellowish in color, with a specific odor and bittersweet taste.
Nanoparticulele de oxid de zinc şi de argint sunt luate în raport masic de 9:1 şi se obţin conform brevetului RU 2451578 C1 2012.05.27, totodată nanoparticulele menţionate, cât şi celelalte ingrediente pot fi procurate în reţeaua liberă de distribuţie a ingredientelor pentru fabricarea remediilor medicamentoase. The nanoparticles of zinc oxide and silver are taken in a mass ratio of 9:1 and are obtained according to the patent RU 2451578 C1 2012.05.27, at the same time the mentioned nanoparticles, as well as the other ingredients can be purchased in the free distribution network of ingredients for the manufacture of remedies medicines.
Condiţionarea siropului se efectuează în flacoane din tereftalat de polietilenă cu volumul de 100 ml şi se etanşează cu dopuri din polietilenă. The conditioning of the syrup is carried out in polyethylene terephthalate bottles with a volume of 100 ml and sealed with polyethylene caps.
Termenul de valabilitate - 3 ani, la temperatura de până la 25°C. Shelf life - 3 years, at a temperature of up to 25°C.
Exemplu concret de realizare Concrete example of realization
Pacienta A., 57 ani, acuze la eructaţie cu miros fetid, greutate în regiunea epigastrică, meteorism, dureri gastrice ce se intensifică după alimentaţie. FEGPS - mucoasa gastrică atrofică, pliurile mucoase sunt denivelate. Pacienta a primit tratament conform metodei revendicate, adică zilnic, per os, câte 100 ml de sirop nutriţional dimineaţa şi sera cu 20 min înainte de masă. Cura de tratament a constituit 3 luni. După aceasta, la investigaţiile efectuate ulterior s-a stabilit dispariţia semnelor clinice şi ameliorarea stării pacientei. Efecte adverse în cazul tratamentului efectuat conform metodei revendicate nu s-au manifestat. Pacienta a fost monitorizată pe parcursul unui an, recidive nu s-au depistat. Patient A., 57 years old, complains of belching with a fetid smell, heaviness in the epigastric region, flatulence, gastric pain that intensifies after eating. FEGPS - atrophic gastric mucosa, the mucosal folds are uneven. The patient received treatment according to the claimed method, i.e. daily, per os, 100 ml of nutritional syrup in the morning and in the evening 20 minutes before the meal. The treatment course was 3 months. After this, during the subsequent investigations, it was established that the clinical signs disappeared and the patient's condition improved. Adverse effects in the case of treatment carried out according to the claimed method did not appear. The patient was monitored for a year, no recurrences were detected.
Conform metodei revendicate au fost trataţi 18 pacienţi, reacţii adverse şi recidive nu s-au depistat. According to the claimed method, 18 patients were treated, adverse reactions and relapses were not detected.
1. MD 3972 C2 2010.08.31 1. MD 3972 C2 2010.08.31
2. RU 2034560 C1 1995.05.10 2. RU 2034560 C1 1995.05.10
3. WO 9102535 A1 1991.03.07 3. WO 9102535 A1 1991.03.07
4. Регистр лекарственных средств. Энциклопедия лекарств. Выпуск 21, 2012, p. 1426 4. Register of medicines. Encyclopedia of medicines. Issue 21, 2012, p. 1426
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDA20130088A MD4341C1 (en) | 2013-11-21 | 2013-11-21 | Syrup for the treatment of gastric precancerous conditions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDA20130088A MD4341C1 (en) | 2013-11-21 | 2013-11-21 | Syrup for the treatment of gastric precancerous conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD4341B1 MD4341B1 (en) | 2015-04-30 |
| MD4341C1 true MD4341C1 (en) | 2015-11-30 |
Family
ID=53002924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20130088A MD4341C1 (en) | 2013-11-21 | 2013-11-21 | Syrup for the treatment of gastric precancerous conditions |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD4341C1 (en) |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991002535A1 (en) * | 1989-08-11 | 1991-03-07 | Basil, Inc. | Cancer prevention composition and method |
| DE4032163C2 (en) * | 1990-10-10 | 1995-03-30 | Gradinger F Hermes Pharma | S-retinoyl-L-aminomercapto compounds and intermediates, processes for their preparation and their use |
| DE4032187C2 (en) * | 1990-10-10 | 1995-03-30 | Gradinger F Hermes Pharma | N-Retinoyl-L-aminomercapto compounds and intermediates, process for their preparation and their use |
| RU2034560C1 (en) * | 1993-05-18 | 1995-05-10 | Товарищество с ограниченной ответственностью "Фитолон" | Cancer prevention "clamin" remedy |
| CN1093402C (en) * | 1998-08-11 | 2002-10-30 | 苏乐群 | Gastritis treating tablet |
| RU2205656C1 (en) * | 2002-06-27 | 2003-06-10 | Общество с ограниченной ответственностью Фирма "ЭЙКОСЪ" | Biologically active supplement "antiyazvennye" for prophylaxis and supporting therapy in digestive tract diseases |
| NZ529115A (en) * | 2001-04-20 | 2005-08-26 | Boehringer Ingelheim Pharma | Use of probucol, ascorbic acid, vitamin E, dipyridamole and mopidamol for treatment and prevention of NO-dependent microcirculation disorders |
| CN1698646A (en) * | 2005-04-29 | 2005-11-23 | 朱舜时 | Medicine composition for treating atrophic gastritis |
| CN1927311A (en) * | 2006-09-19 | 2007-03-14 | 陈楚挺 | Drug for treating chronic atrophic gastritis precancerous lesion and finished capsule product thereof |
| MD3972C2 (en) * | 2009-03-11 | 2010-07-31 | Ион МЕРЕУЦЭ | Remedy and method for treating precancerous conditions |
| RU2473357C2 (en) * | 2011-02-24 | 2013-01-27 | Общество с ограниченной ответственностью "ДИНАМИК ДЕВЕЛОПМЕНТ ЛАБОРАТОРИЗ" | Liquid composition improving working performance and possessing adaptogenic, wound-healing and anti-inflammatory action |
| CN103230431A (en) * | 2013-04-27 | 2013-08-07 | 洪士炀 | Medicine for treating stomach disease and application |
| CN103082299B (en) * | 2012-12-26 | 2014-07-30 | 东莞市照燕生物科技有限公司 | Nutritional healthcare product for clearing bowels and expelling toxin |
-
2013
- 2013-11-21 MD MDA20130088A patent/MD4341C1/en not_active IP Right Cessation
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991002535A1 (en) * | 1989-08-11 | 1991-03-07 | Basil, Inc. | Cancer prevention composition and method |
| DE4032163C2 (en) * | 1990-10-10 | 1995-03-30 | Gradinger F Hermes Pharma | S-retinoyl-L-aminomercapto compounds and intermediates, processes for their preparation and their use |
| DE4032187C2 (en) * | 1990-10-10 | 1995-03-30 | Gradinger F Hermes Pharma | N-Retinoyl-L-aminomercapto compounds and intermediates, process for their preparation and their use |
| RU2034560C1 (en) * | 1993-05-18 | 1995-05-10 | Товарищество с ограниченной ответственностью "Фитолон" | Cancer prevention "clamin" remedy |
| CN1093402C (en) * | 1998-08-11 | 2002-10-30 | 苏乐群 | Gastritis treating tablet |
| NZ529115A (en) * | 2001-04-20 | 2005-08-26 | Boehringer Ingelheim Pharma | Use of probucol, ascorbic acid, vitamin E, dipyridamole and mopidamol for treatment and prevention of NO-dependent microcirculation disorders |
| RU2205656C1 (en) * | 2002-06-27 | 2003-06-10 | Общество с ограниченной ответственностью Фирма "ЭЙКОСЪ" | Biologically active supplement "antiyazvennye" for prophylaxis and supporting therapy in digestive tract diseases |
| CN1698646A (en) * | 2005-04-29 | 2005-11-23 | 朱舜时 | Medicine composition for treating atrophic gastritis |
| CN1927311A (en) * | 2006-09-19 | 2007-03-14 | 陈楚挺 | Drug for treating chronic atrophic gastritis precancerous lesion and finished capsule product thereof |
| MD3972C2 (en) * | 2009-03-11 | 2010-07-31 | Ион МЕРЕУЦЭ | Remedy and method for treating precancerous conditions |
| RU2473357C2 (en) * | 2011-02-24 | 2013-01-27 | Общество с ограниченной ответственностью "ДИНАМИК ДЕВЕЛОПМЕНТ ЛАБОРАТОРИЗ" | Liquid composition improving working performance and possessing adaptogenic, wound-healing and anti-inflammatory action |
| CN103082299B (en) * | 2012-12-26 | 2014-07-30 | 东莞市照燕生物科技有限公司 | Nutritional healthcare product for clearing bowels and expelling toxin |
| CN103230431A (en) * | 2013-04-27 | 2013-08-07 | 洪士炀 | Medicine for treating stomach disease and application |
Non-Patent Citations (1)
| Title |
|---|
| Регистр лекарственных средств. Энциклопедия лекарств. Выпуск 21, 2012, p. 1426 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MD4341B1 (en) | 2015-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stansbury et al. | Promoting healthy thyroid function with iodine, bladderwrack, guggul and iris | |
| CN103223128B (en) | A traditional Chinese medicine composition for improving nutritional anemia and its preparation method | |
| CN110800997A (en) | Special clinical nutrition formula for thyroid cancer and preparation method thereof | |
| WO2015190875A1 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for preventing and treating retinal diseases | |
| US9943503B1 (en) | Pharmaceutical composition for treating bacterial and viral infections | |
| CN106165905A (en) | A kind of calcium adds vitamine soft capsule and preparation method | |
| CN102268098B (en) | Method for preparing yerbadetajo herb polyferose complex and application thereof | |
| MD4341C1 (en) | Syrup for the treatment of gastric precancerous conditions | |
| CN105395644A (en) | Traditional Chinese medicinal composition for preventing and treating coccidiosis in chicken as well as preparation method and application of traditional Chinese medicinal composition | |
| US10149831B1 (en) | Pharmaceutical composition for treating bacterial and viral infections | |
| US20190247360A1 (en) | Pharmaceutical Composition for Treating Bacterial and Viral infections | |
| JP4610730B2 (en) | Composition for calcium supplementation | |
| CN114468291A (en) | A kind of inositol composition for improving female infertility and preparation method thereof | |
| RU2821515C1 (en) | Composition based on vegetal raw materials for prevention of inflammatory diseases of kidneys and urinary tract | |
| CN104027351A (en) | Oral composition of supplement | |
| BR112016005727B1 (en) | USE OF A COCOA POLYPHENOL EXTRACT TO PREPARE A COMPOSITION FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | |
| CN102049035B (en) | A kind of starch polysaccharide iron compound preparation | |
| US11931393B2 (en) | Biologically active food additive for normalizing the function of the thyroid gland | |
| RU2442599C2 (en) | HOMEOPATHIC MEDICATION AND BIOLOGICALLY ACTIVE ADDITIVE CONTAINING Nisylen, Cepa, Euphrasia, Belladonna AND/OR Mericulis solubilis | |
| US10166265B1 (en) | Pharmaceutical composition for treating bacterial and viral infections | |
| CN103520361B (en) | A kind of lycopene compound preparation with enhancing immunity and chronic disease health-care effect | |
| Bilovol et al. | PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC POTENTIAL OF ZINGIBER OFFICINALE ROSCOE | |
| Peres | Iodine, Ingesting or not | |
| CN104274625B (en) | A kind of application of Chinese medicine in the few sperm disease for the treatment of | |
| KR102180165B1 (en) | A synergistic composition for treating anemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG4A | Patent for invention issued | ||
| KA4A | Patent for invention lapsed due to non-payment of fees (with right of restoration) | ||
| MM4A | Patent for invention definitely lapsed due to non-payment of fees |